Business Description
Evommune Inc
NAICS : 541714
SIC : 2833
ISIN : US30054Y1073
Total Employee Number:
48Description
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 24.76 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 9.43 | |||||
Beneish M-Score | 41.72 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 26.45 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 30.51 | |||||
9-Day RSI | 36.01 | |||||
14-Day RSI | 39.87 | |||||
3-1 Month Momentum % | -36.64 | |||||
6-1 Month Momentum % | -44.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.68 | |||||
Quick Ratio | 11.68 | |||||
Cash Ratio | 11.48 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1018.93 | |||||
Net Margin % | -946.68 | |||||
EBITDA Margin % | -1003.55 | |||||
FCF Margin % | -744.19 | |||||
OCF Margin % | -741.53 | |||||
ROE % | -109.23 | |||||
ROA % | -45.95 | |||||
ROIC % | -170.04 | |||||
ROC (Joel Greenblatt) % | -2174.69 | |||||
ROCE % | -52.87 | |||||
Moat Score | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 36.96 | |||||
PB Ratio | 1.6 | |||||
Price-to-Tangible-Book | 1.6 | |||||
EV-to-EBIT | -2.48 | |||||
EV-to-EBITDA | -2.52 | |||||
EV-to-Revenue | 25.26 | |||||
EV-to-Forward-Revenue | 126.31 | |||||
EV-to-FCF | -3.39 | |||||
| Price-to-Net-Current-Asset-Value | 2.47 | |||||
| Price-to-Net-Cash | 2.52 | |||||
Earnings Yield (Greenblatt) % | -40.32 | |||||
FCF Yield % | -16.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:EVMN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evommune Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10 | ||
| EPS (TTM) ($) | -3.375 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 39.87 | ||
| 14-Day ATR ($) | 0.800269 | ||
| 20-Day SMA ($) | 13.618 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 10.47 - 33.2 | ||
| Shares Outstanding (Mil) | 36.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evommune Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evommune Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-05 | In 181 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-05 | In 181 days | ||
| Third quarter earnings results for 2026 | 2026-11-30 | In 86 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 13.02 (+0.31%) | ||
| General meeting for 2025 | 2026-06-02 11:30 | 22.17 (-4.56%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 23.83 (-0.38%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-11 13:00 | 24.00 (-5.29%) | ||
| Annual report for 2025 | 2026-03-05 | 23.59 (-0.88%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 23.59 (-0.88%) |
Show
Entries
Evommune Inc Frequently Asked Questions
What is Evommune Inc(EVMN)'s stock price today?
The current price of EVMN is $12.27. The 52 week high of EVMN is $33.20 and 52 week low is $10.47.
When is next earnings date of Evommune Inc(EVMN)?
The next earnings date of Evommune Inc(EVMN) is 2026-11-30 Est..
Does Evommune Inc(EVMN) pay dividends? If so, how much?
Evommune Inc(EVMN) does not pay dividend.
Press Release
Articles on Evommune Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers